Platelet STING agonism and venous thrombosis: translational implications for improved disease outcomes

Jessica N Filderman; Jason J Luke; Walter J Storkus

doi:10.1093/jleuko/qiad073

Platelet STING agonism and venous thrombosis: translational implications for improved disease outcomes

J Leukoc Biol. 2023 Sep 1;114(3):195-198. doi: 10.1093/jleuko/qiad073.

Authors

Jessica N Filderman¹, Jason J Luke^{2

3}, Walter J Storkus^{1

3

4}

Affiliations

¹ Department of Immunology, University of Pittsburgh School of Medicine, W1110 Thomas E. Starzl Biomedical Sciences Tower, 200 Lothrop Street, Pittsburgh, PA 15213, USA.
² Department of Medicine, University of Pittsburgh School of Medicine, 1.27C Research Pavilion, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA 15213, USA.
³ Cancer Immunology and Immunotherapy Program, Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA 15213, USA.
⁴ Department of Dermatology, Pathology and Bioengineering, University of Pittsburgh School of Medicine, W1151 BST, 200 Lothrop Street, Pittsburgh, PA 15213, USA.

PMID: 37399019
PMCID: PMC10473254 (available on 2024-09-01)
DOI: 10.1093/jleuko/qiad073

No abstract available

Keywords: STING agonist; STXBP2; cGAS; coagulopathy; neutrophil extracellular traps; neutrophils; palmitoylation; platelets; sepsis; stimulator of interferon genes; targeted therapy; thrombin; vasculature.

Publication types

Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Comment

MeSH terms

Blood Platelets
Extracellular Traps*
Humans
Neutrophils
Venous Thrombosis* / drug therapy

Substances

STING1 protein, human

Publication types

MeSH terms

Substances

Grants and funding